BACKGROUND: Etomidate is a sedative-hypnotic that is often given as a single intravenous bolus but rarely as an infusion because it suppresses adrenocortical function. Methoxycarbonyl etomidate and (R)-ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (carboetomidate) are etomidate analogs that do not produce significant adrenocortical suppression when given as a single bolus. However, the effects of continuous infusions on adrenocortical function are unknown. In this study, we compared the effects of continuous infusions of etomidate, methoxycarbonyl etomidate, and carboetomidate on adrenocortical function in a rat model. METHODS: A closed-loop system using the electroencephalographic burst suppression ratio as the feedback was used to administer continuous infusions of etomidate, methoxycarbonyl etomidate, or carboetomidate to Sprague-Dawley rats. Adrenocortical function was assessed during and after infusion by repetitively administering adrenocorticotropic hormone 1-24 and measuring serum corticosterone concentrations every 30 min. RESULTS: The sedative-hypnotic doses required to maintain a 40% burst suppression ratio in the presence of isoflurane, 1%, and the rate of burst suppression ratio recovery on infusion termination varied (methoxycarbonyl etomidate > carboetomidate > etomidate). Serum corticosterone concentrations were reduced by 85% and 56% during 30-min infusions of etomidate and methoxycarbonyl etomidate, respectively. On infusion termination, serum corticosterone concentrations recovered within 30 min with methoxycarbonyl etomidate but persisted beyond an hour with etomidate. Carboetomidate had no effect on serum corticosterone concentrations during or after continuous infusion. CONCLUSIONS: Our results suggest that methoxycarbonyl etomidate and carboetomidate may have clinical utility as sedative-hypnotic maintenance agents when hemodynamic stability is desirable.
BACKGROUND:Etomidate is a sedative-hypnotic that is often given as a single intravenous bolus but rarely as an infusion because it suppresses adrenocortical function. Methoxycarbonyl etomidate and (R)-ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (carboetomidate) are etomidate analogs that do not produce significant adrenocortical suppression when given as a single bolus. However, the effects of continuous infusions on adrenocortical function are unknown. In this study, we compared the effects of continuous infusions of etomidate, methoxycarbonyl etomidate, and carboetomidate on adrenocortical function in a rat model. METHODS: A closed-loop system using the electroencephalographic burst suppression ratio as the feedback was used to administer continuous infusions of etomidate, methoxycarbonyl etomidate, or carboetomidate to Sprague-Dawley rats. Adrenocortical function was assessed during and after infusion by repetitively administering adrenocorticotropic hormone 1-24 and measuring serum corticosterone concentrations every 30 min. RESULTS: The sedative-hypnotic doses required to maintain a 40% burst suppression ratio in the presence of isoflurane, 1%, and the rate of burst suppression ratio recovery on infusion termination varied (methoxycarbonyl etomidate > carboetomidate > etomidate). Serum corticosterone concentrations were reduced by 85% and 56% during 30-min infusions of etomidate and methoxycarbonyl etomidate, respectively. On infusion termination, serum corticosterone concentrations recovered within 30 min with methoxycarbonyl etomidate but persisted beyond an hour with etomidate. Carboetomidate had no effect on serum corticosterone concentrations during or after continuous infusion. CONCLUSIONS: Our results suggest that methoxycarbonyl etomidate and carboetomidate may have clinical utility as sedative-hypnotic maintenance agents when hemodynamic stability is desirable.
Authors: Molly Sarkar; Peter C Laussen; David Zurakowski; Avinash Shukla; Barry Kussman; Kirsten C Odegard Journal: Anesth Analg Date: 2005-09 Impact factor: 5.108
Authors: Joseph F Cotten; Stuart A Forman; Joydev K Laha; Gregory D Cuny; S Shaukat Husain; Keith W Miller; Hieu H Nguyen; Elizabeth W Kelly; Deirdre Stewart; Aiping Liu; Douglas E Raines Journal: Anesthesiology Date: 2010-03 Impact factor: 7.892
Authors: M M Struys; T De Smet; L F Versichelen; S Van De Velde; R Van den Broecke; E P Mortier Journal: Anesthesiology Date: 2001-07 Impact factor: 7.892
Authors: Bryan Li; Martin Berliner; Richard Buzon; Charles K-F Chiu; Stephen T Colgan; Takushi Kaneko; Nandell Keene; William Kissel; Tung Le; Kyle R Leeman; Brian Marquez; Ronald Morris; Lisa Newell; Silke Wunderwald; Michael Witt; John Weaver; Zhijun Zhang; Zhongli Zhang Journal: J Org Chem Date: 2006-11-24 Impact factor: 4.354
Authors: Ilse M Zolle; Michael L Berger; Friedrich Hammerschmidt; Stefanie Hahner; Andreas Schirbel; Biljana Peric-Simov Journal: J Med Chem Date: 2008-03-19 Impact factor: 7.446
Authors: Joseph F Cotten; S Shaukat Husain; Stuart A Forman; Keith W Miller; Elizabeth W Kelly; Hieu H Nguyen; Douglas E Raines Journal: Anesthesiology Date: 2009-08 Impact factor: 7.892
Authors: Ri Le Ge; Ervin Pejo; Marian Haburcak; S Shaukat Husain; Stuart A Forman; Douglas E Raines Journal: Anesth Analg Date: 2011-11-03 Impact factor: 5.108
Authors: Sivananthaperumal Shanmugasundararaj; Xiaojuan Zhou; Jens Neunzig; Rita Bernhardt; Joseph F Cotten; Rile Ge; Keith W Miller; Douglas E Raines Journal: Anesth Analg Date: 2013-03-14 Impact factor: 5.108
Authors: Daniel Diaz-Gil; Friederike Haerter; Shane Falcinelli; Shweta Ganapati; Gaya K Hettiarachchi; Jeroen C P Simons; Ben Zhang; Stephanie D Grabitz; Ingrid Moreno Duarte; Joseph F Cotten; Katharina Eikermann-Haerter; Hao Deng; Nancy L Chamberlin; Lyle Isaacs; Volker Briken; Matthias Eikermann Journal: Anesthesiology Date: 2016-08 Impact factor: 7.892
Authors: ShiNung Ching; Max Y Liberman; Jessica J Chemali; M Brandon Westover; Jonathan D Kenny; Ken Solt; Patrick L Purdon; Emery N Brown Journal: Anesthesiology Date: 2013-10 Impact factor: 7.892